Recordati Industria Chimica e Farmaceutica SpA
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
469 / 1328
Position in country
312 / 520
Return on Assets, %
9.4
-2.7
Debt to Equity, %
107.2
19.2
Intangible assets and goodwill, %
64.5
3.6
Revenue CAGR 3Y, %
12.8
8.5
Total Equity change 1Y, %
12.4
0
Revenue Y, % chg
16
0.5
P/E
26.2
22.7
P/BV
6
1.5
P/S
4.9
2.3
EV/S
5.7
2.4
EV/EBITDA
16.6
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
321
51.3
Forward P/E
19.6
15.6
Dividend Yield, %
2.4
1.7
Forward Dividend Yield, %
11.7
0.2
Expected dividend per share
1.5
0
Dividend Ex Date
2024-05-20
Competitors
Ranks
-
Novo Nordisk A/S
00%
-
Sanofi SA
00%
-
AstraZeneca PLC
00%
-
Recordati Industria Chimica e Farmaceutica SpA
00%
-
Eli Lilly and Co
00%
-
Roche Holding AG
00%
-
Novartis AG
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
-
Pfizer Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Italy
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
11083.1
Ticker
RICFY.PK
ISIN
US75625L1008
IPO date
1984-01-01
Availability on Russian exchanges
No
Reporting for
Date fact. publication of reports
Company Description
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: